

Avatrombopag hydrochloride Biochemical

Avatrombopag hydrochloride

CATALOG #
AAA228770


PRODUCT SYNONYMS

Avatrombopag hydrochloride; Avatrombopag hydrochloride biochemical


PRODUCT SPECIFICATIONS

Purity/Purification	98%
CAS	570403-17-7
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
In vitro	Avatrombopag hydrochloride (0.3-3mg/kg; p.o.; daily for 14 days) increases the number of human platelets in NOD/SCID mice transplanted with human FL CD34 + cells[1]. Animal Model: NOD/SCID mice (transplanted with human FL CD34+cells)[1]. Dosage: 0.3, 1, and 3mg/kg. Administration: P.o.; daily for 14 days. Result: Dose-dependently increased the number of human platelets, resulting in approximately a 2.7-fold increase at 1 mg/kg/d and a 3.0-fold increase at 3mg/kg/d on day 14 after the start of administration.
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure
Benzyl-PEG4-Azido, CAS 86770-71-0



Structure
Benzyl-PEG4-Azido, CAS 86770-71-0

ADDITIONAL INFORMATION

Related Product Information for Avatrombopag hydrochloride biochemical

Avatrombopag (AKR-501) hydrochloride is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC 50 =3.3 nM). Avatrombopag hydrochloride mimics the biological activities of TPO. Avatrombopag hydrochloride increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag hydrochloride is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

